GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Ltd (NYSE:BHVN) » Definitions » Net Change in Cash

Biohaven (Biohaven) Net Change in Cash : $-3.66 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biohaven Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Biohaven's Net Change in Cash for the three months ended in Mar. 2024 was $-65.19 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $-3.66 Mil.

Biohaven Net Change in Cash Historical Data

The historical data trend for Biohaven's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Net Change in Cash Chart

Biohaven Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Change in Cash
73.59 -6.45 165.55 9.52

Biohaven Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.01 11.36 -75.96 126.13 -65.19

Biohaven Net Change in Cash Calculation

Biohaven's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-331.725+129.83+211.908+-0.497
=9.52

Biohaven's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-102.637+34.031+3.423+-0.006
=-65.19

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biohaven Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Biohaven's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Biohaven (Biohaven) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biohaven Ltd (NYSE:BHVN) » Definitions » Net Change in Cash
Comparable Companies
ZLAB NTLA RVMD FTRE IBRX MLTX DNLI MDGL XENE PRTA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
215 Church Street, New Haven, CT, USA, 06510
Website
https://www.biohavenpharma.com
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.
Executives
Irina Antonijevic director 215 CHURCH STREET, NEW HAVEN CT 06510
John W Childs director 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Vlad Coric director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Matthew Buten officer: Chief Financial Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
George C. Clark officer: VP, Chief Accounting Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Kimberly Gentile officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Kishan Mehta director 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd. 10 percent owner 215 CHURCH STREET, NEW HAVEN CT 06510
Bruce Car officer: Chief Scientific Officer AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139